>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

3.07 0.02 (0.66%) 09/04/2026
Anixa Biosciences, Inc. (ANIX)
Performance
Historical returns
1D
0.66%
1W
-8.36%
1M
-9.97%
3M
17.18%
6M
5.50%
1Y
3.37%
5Y
-40.73%
Snapshot
Key statistics
Close
3.07
Change
0.02
Change %
0.66%
Open
3.03
Day Range
3.00 – 3.11
Volume
367,797
Avg Vol (20d)
275,486
Rel Vol
1.34x
52W Range
2.32 - 5.46
vs 52W High
-43.77%
vs 52W Low
32.33%
Gap
-0.22
Market Cap
USD 104.45M
Beta
0.51
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
4 bullish · 1 bearish points
Bullish view
  • Has recovered 30.6% off the 52-week low of $2.35.
  • Outperformed the S&P 500 by 19.1% over the last quarter (+23.8% against +4.7%).
  • Beat consensus EPS in 7 of the last 8 quarters.
  • The Q2 '26 quarter beat on EPS by $0.03 (30.0% above consensus).
Bearish view
  • Still 41.2% below its 52-week high of $5.22.
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Sep 4
2026
$3.07 0.66%Latest
Anixa Biosciences rose 0.66% to $3.07, on 1.4× average volume. The move left the stock 41.2% below its 52-week high.
Sep 2
2026
$3.13 4.57%
Anixa Biosciences fell 4.57% to $3.13, its biggest one-day drop in 3 weeks, on 1.4× average volume. This was largely stock-specific: the S&P 500 gained 0.44% while Healthcare peers (XLV) rose 0.75% that session, leaving about 4.8 points of the move unexplained by the market after adjusting for a 0.51 beta. Shares opened with a 1.37% gap up and reversed through the session, closed near the session low (4% of the day's range), lost their 200-day moving average and marked a 6th consecutive decline.
Aug 31
2026
$3.35 3.74%
Anixa Biosciences fell 3.74% to $3.35, its biggest one-day drop in 3 weeks, on 1.6× average volume. This was largely stock-specific: the S&P 500 fell 0.30% while Healthcare peers (XLV) fell 0.36% that session, leaving about 3.4 points of the move unexplained by its sector. Shares opened with a 1.44% gap down, closed near the session low (13% of the day's range), lost their 20-day moving average and marked a 4th consecutive decline.
Aug 19
2026
$3.71 8.16%
Anixa Biosciences rose 8.16% to $3.71, a 2.0σ move against its 60-day volatility, on 2.6× average volume. Roughly 4.7 points were stock-specific — the S&P 500 gained 0.21% while Healthcare peers (XLV) rose 3.51% alongside it. Shares opened with an 8.16% gap up.
Aug 17
2026
$3.49 9.75%
Anixa Biosciences rose 9.75% to $3.49, its biggest one-day gain in 2 months and a 2.5σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.47% while Healthcare peers (XLV) fell 0.19% that session, leaving about 9.9 points of the move unexplained by its sector. Shares closed near the session high (97% of the day's range) and reclaimed their 20- and 200-day moving averages. Historically, after 2.5σ-or-larger up days, Anixa Biosciences returned +0.79% on average over the following 5 sessions (50% positive, n=22).
Aug 10
2026
$3.25 4.97%
Anixa Biosciences fell 4.97% to $3.25, its biggest one-day drop in 2 weeks. This was largely stock-specific: the S&P 500 gained 0.01% while Healthcare peers (XLV) rose 1.84% that session, leaving about 5.0 points of the move unexplained by the market after adjusting for a 0.51 beta. Shares opened with a 2.92% gap down and closed near the session low (16% of the day's range).
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month2.99 +2.68%
on 09/03/26
Open 3.43
3.87 -20.72%
on 08/25/26
-0.36 (-10.50%)
since 08/06/26
3-Month2.32 +32.33%
on 06/11/26
Open 2.48
3.87 -20.72%
on 08/25/26
+0.59 (+23.79%)
since 06/05/26
6-Month2.32 +32.33%
on 06/11/26
Open 2.85
3.87 -20.72%
on 08/25/26
+0.22 (+7.72%)
since 03/06/26
YTD2.32 +32.33%
on 06/11/26
Open 3.16
3.87 -20.72%
on 08/25/26
-0.09 (-2.85%)
since 01/02/26
52-Week2.32 +32.33%
on 06/11/26
Open 2.97
5.46 -43.77%
on 12/09/25
+0.10 (+3.37%)
since 09/04/25
5-Year2.07 +48.31%
on 01/14/25
Open 5.25
6.45 -52.40%
on 04/17/23
-2.18 (-41.52%)
since 08/27/21
New Highs
Historical highs
5-Day
0×
-8.36% from peak
1-Month
2×
-17.25% from peak
3-Month
9×
-18.13% from peak
6-Month
6×
-18.13% from peak
YTD
6×
-18.13% from peak
52-Week
8×
-41.19% from peak
2-Year
7×
-41.19% from peak
3-Year
10×
-41.19% from peak
5-Year
4×
-50.08% from peak
10-Year
13×
-57.00% from peak
Financial SnapshotFY 2025
Full financials
Revenue
n/a
Net Income
-USD 11.03M
-13.2% YoY
EPS
-0.34
-12.8% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 10.99M
Free Cash Flow
-USD 7.17M
ROE
-72.7%
ROA
-68.6%
Debt / Equity
0.01x
net debt -USD 1.04M
Cash & Equiv.
USD 1.24M
News
All news
09/03 08:00 ET · prnewswire.com
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company...
08/24 08:55 ET · prnewswire.com
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four...
08/18 08:45 ET · prnewswire.com
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined...
07/22 13:02 ET · zacks.com
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
07/22 08:17 ET · zacks.com
New Strong Buy Stocks for July 22nd
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
07/14 08:33 ET · prnewswire.com
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN JOSE, Calif., July 14, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"...
07/06 08:30 ET · prnewswire.com
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc....
06/29 08:45 ET · prnewswire.com
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations...

Market News ×
Loading news…